{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T09:15:31Z","timestamp":1779095731094,"version":"3.51.4"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"DOI":"10.1038\/s41401-026-01817-6","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T07:31:09Z","timestamp":1779089469000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting fusion proteins in solid tumors: from oncogenic mechanisms to clinical interventions"],"prefix":"10.1038","author":[{"given":"Yue-ning","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-fan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-liang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-wen","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiao-jun","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei-dan","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"1817_CR1","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.ccell.2018.01.018","volume":"33","author":"A Banito","year":"2018","unstructured":"Banito A, Li X, Laporte AN, Roe JS, Sanchez-Vega F, Huang CH, et al. The SS18-SSX oncoprotein hijacks KDM2B-PRC1.1 to drive synovial sarcoma. Cancer Cell. 2018;33:527\u201341.e8.","journal-title":"Cancer Cell"},{"key":"1817_CR2","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s12032-012-0412-8","volume":"30","author":"M Cantile","year":"2013","unstructured":"Cantile M, Marra L, Franco R, Ascierto P, Liguori G, De Chiara A, et al. Molecular detection and targeting of EWSR1 fusion transcripts in soft tissue tumors. Med Oncol Northwood Lond Engl. 2013;30:412.","journal-title":"Med Oncol Northwood Lond Engl"},{"key":"1817_CR3","doi-asserted-by":"publisher","first-page":"iii4","DOI":"10.1093\/annonc\/mdw301","volume":"27","author":"B Hallberg","year":"2016","unstructured":"Hallberg B, Palmer RH. The role of the ALK receptor in cancer biology. Ann Oncol. 2016;27:iii4\u201315.","journal-title":"Ann Oncol"},{"key":"1817_CR4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1021\/acsptsci.9b00019","volume":"2","author":"NS Latysheva","year":"2019","unstructured":"Latysheva NS, Babu MM. Molecular signatures of fusion proteins in cancer. ACS Pharmacol Transl Sci. 2019;2:122\u201333.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"1817_CR5","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/35015097","volume":"405","author":"C Richardson","year":"2000","unstructured":"Richardson C, Jasin M. Frequent chromosomal translocations induced by DNA double-strand breaks. Nature. 2000;405:697\u2013700.","journal-title":"Nature"},{"key":"1817_CR6","doi-asserted-by":"publisher","first-page":"dmm049078","DOI":"10.1242\/dmm.049078","volume":"14","author":"S Alonso","year":"2021","unstructured":"Alonso S, Dow LE. Engineering chromosome rearrangements in cancer. Dis Model Mech. 2021;14:dmm049078.","journal-title":"Dis Model Mech"},{"key":"1817_CR7","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nrc3947","volume":"15","author":"F Mertens","year":"2015","unstructured":"Mertens F, Johansson B, Fioretos T, Mitelman F. The emerging complexity of gene fusions in cancer. Nat Rev Cancer. 2015;15:371\u201381.","journal-title":"Nat Rev Cancer"},{"key":"1817_CR8","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1582-4934.2011.01415.x","volume":"16","author":"S Medves","year":"2012","unstructured":"Medves S, Demoulin J-B. Tyrosine kinase gene fusions in cancer: Translating mechanisms into targeted therapies. J Cell Mol Med. 2012;16:237\u201348.","journal-title":"J Cell Mol Med"},{"key":"1817_CR9","first-page":"434","volume":"25","author":"A Va\u0161\u00edkov\u00e1","year":"2012","unstructured":"Va\u0161\u00edkov\u00e1 A. EML4-ALK fusion gene in patients with lung carcinoma: biology, diagnostics and targeted therapy. Klin Onkol Cas Ceske Slov Onkol Spolecnosti. 2012;25:434\u20139.","journal-title":"Klin Onkol Cas Ceske Slov Onkol Spolecnosti"},{"key":"1817_CR10","unstructured":"Yang T, Liu H, Chen J. EML4-ALK fusion gene in lung cancer and its biological function. Chin J Lung Cancer 2012;15:112\u20136."},{"key":"1817_CR11","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00018-015-2117-6","volume":"73","author":"R Bayliss","year":"2016","unstructured":"Bayliss R, Choi J, Fennell DA, Fry AM, Richards MW. Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs. Cell Mol Life Sci CMLS. 2016;73:1209\u201324.","journal-title":"Cell Mol Life Sci CMLS"},{"key":"1817_CR12","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3892\/ol.2022.13397","volume":"24","author":"Y Lei","year":"2022","unstructured":"Lei Y, Lei Y, Shi X, Wang J. EML4-ALK fusion gene in non-small cell lung cancer. Oncol Lett. 2022;24:277.","journal-title":"Oncol Lett"},{"key":"1817_CR13","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4\u2013ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561\u20136.","journal-title":"Nature"},{"key":"1817_CR14","doi-asserted-by":"publisher","first-page":"5821","DOI":"10.3390\/ijms24065821","volume":"24","author":"SY Cheon","year":"2023","unstructured":"Cheon SY, Kwon S. Molecular anatomy of the EML4-ALK fusion protein for the development of novel anticancer drugs. Int J Mol Sci. 2023;24:5821.","journal-title":"Int J Mol Sci"},{"key":"1817_CR15","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1016\/j.cell.2021.03.031","volume":"184","author":"A Tulpule","year":"2021","unstructured":"Tulpule A, Guan J, Neel DS, Allegakoen HR, Lin YP, Brown D, et al. Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules. Cell. 2021;184:2649\u201364.e18.","journal-title":"Cell"},{"key":"1817_CR16","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/1878-0261.13446","volume":"17","author":"M Elshatlawy","year":"2023","unstructured":"Elshatlawy M, Sampson J, Clarke K, Bayliss R. EML4-ALK biology and drug resistance in non-small cell lung cancer: A new phase of discoveries. Mol Oncol. 2023;17:950\u201363.","journal-title":"Mol Oncol"},{"key":"1817_CR17","doi-asserted-by":"publisher","first-page":"8673","DOI":"10.1158\/0008-5472.CAN-08-2097","volume":"68","author":"DTW Jones","year":"2008","unstructured":"Jones DTW, Kocialkowski S, Liu L, Pearson DM, B\u00e4cklund LM, Ichimura K, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008;68:8673\u20137.","journal-title":"Cancer Res"},{"key":"1817_CR18","first-page":"782","volume":"26","author":"P Xiao","year":"2023","unstructured":"Xiao P, Zhong D. Research progress of BRAF fusion in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi Chin J Lung Cancer. 2023;26:782\u20138.","journal-title":"Zhongguo Fei Ai Za Zhi Chin J Lung Cancer"},{"key":"1817_CR19","doi-asserted-by":"publisher","first-page":"456","DOI":"10.21037\/tcr-22-2888","volume":"12","author":"R Rosell","year":"2023","unstructured":"Rosell R, Gonz\u00e1lez-Cao M, Codony-Servat J, Molina-Vila MA, de Las Casas CM, Ito M. Acquired BRAF gene fusions in osimertinib resistant EGFR-mutant non-small cell lung cancer. Transl Cancer Res. 2023;12:456\u201360.","journal-title":"Transl Cancer Res"},{"key":"1817_CR20","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s41388-019-1021-1","volume":"39","author":"F Weinberg","year":"2020","unstructured":"Weinberg F, Griffin R, Fr\u00f6hlich M, Heining C, Braun S, Spohr C, et al. Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains. Oncogene. 2020;39:814\u201332.","journal-title":"Oncogene"},{"key":"1817_CR21","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/ijc.29825","volume":"138","author":"JS Ross","year":"2016","unstructured":"Ross JS, Wang K, Chmielecki J, Gay L, Johnson A, Chudnovsky J, et al. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. Int J Cancer. 2016;138:881\u201390.","journal-title":"Int J Cancer"},{"key":"1817_CR22","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1158\/1078-0432.CCR-23-3981","volume":"30","author":"MF Chen","year":"2024","unstructured":"Chen MF, Yang S-R, Tao JJ, Desilets A, Diamond EL, Wilhelm C, et al. Tumor-agnostic genomic and clinical analysis of BRAF fusions identifies actionable targets. Clin Cancer Res. 2024;30:3812\u201323.","journal-title":"Clin Cancer Res"},{"key":"1817_CR23","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1126\/science.1220834","volume":"337","author":"D Singh","year":"2012","unstructured":"Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science. 2012;337:1231.","journal-title":"Science"},{"key":"1817_CR24","first-page":"855","volume":"123","author":"BC Parker","year":"2013","unstructured":"Parker BC, Annala MJ, Cogdell DE, Granberg KJ, Sun Y, Ji P, et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest. 2013;123:855.","journal-title":"J Clin Invest"},{"key":"1817_CR25","doi-asserted-by":"publisher","first-page":"100641","DOI":"10.1016\/j.esmoop.2022.100641","volume":"7","author":"K Murugesan","year":"2022","unstructured":"Murugesan K, Necchi A, Burn TC, Gjoerup O, Greenstein R, Krook M, et al. Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations. ESMO Open. 2022;7:100641.","journal-title":"ESMO Open"},{"key":"1817_CR26","doi-asserted-by":"publisher","first-page":"108536","DOI":"10.1016\/j.mrrev.2025.108536","volume":"795","author":"J Liu","year":"2025","unstructured":"Liu J, Wang Z. The landscape of FGFR-TACC fusion in adult glioblastoma: from bench to bedside. Mutat Res - Rev Mutat Res. 2025;795:108536.","journal-title":"Mutat Res - Rev Mutat Res"},{"key":"1817_CR27","doi-asserted-by":"publisher","first-page":"8675","DOI":"10.3390\/ijms23158675","volume":"23","author":"H G\u00f6tt","year":"2022","unstructured":"G\u00f6tt H, Uhl E. FGFR3-TACCs3 fusions and their clinical relevance in human glioblastoma. Int J Mol Sci. 2022;23:8675.","journal-title":"Int J Mol Sci"},{"key":"1817_CR28","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.annonc.2020.08.2335","volume":"31","author":"J Laskin","year":"2020","unstructured":"Laskin J, Liu SV, Tolba K, Heining C, Schlenk RF, Cheema P, et al. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents. Ann Oncol. 2020;31:1693\u2013703.","journal-title":"Ann Oncol"},{"key":"1817_CR29","doi-asserted-by":"publisher","first-page":"69450","DOI":"10.18632\/oncotarget.11913","volume":"7","author":"DH Shin","year":"2016","unstructured":"Shin DH, Lee D, Hong DW, Hong SH, Hwang JA, Lee BI, et al. Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung. Oncotarget. 2016;7:69450\u201365.","journal-title":"Oncotarget"},{"key":"1817_CR30","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1158\/2159-8290.CD-13-0633","volume":"4","author":"L Fernandez-Cuesta","year":"2014","unstructured":"Fernandez-Cuesta L, Plenker D, Osada H, Sun R, Menon R, Leenders F, et al. CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov. 2014;4:415\u201322.","journal-title":"Cancer Discov"},{"key":"1817_CR31","doi-asserted-by":"publisher","first-page":"15981","DOI":"10.3390\/ijms242115981","volume":"24","author":"J Vargas","year":"2023","unstructured":"Vargas J, Pantouris G. Analysis of CD74 occurrence in oncogenic fusion proteins. Int J Mol Sci. 2023;24:15981.","journal-title":"Int J Mol Sci"},{"key":"1817_CR32","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.trecan.2021.11.003","volume":"8","author":"M Nagasaka","year":"2022","unstructured":"Nagasaka M, Ou SHI. NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis. Trends Cancer. 2022;8:242\u201358.","journal-title":"Trends Cancer"},{"key":"1817_CR33","doi-asserted-by":"publisher","first-page":"5736","DOI":"10.1038\/sj.onc.1204599","volume":"20","author":"FG Barr","year":"2001","unstructured":"Barr FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene. 2001;20:5736\u201346.","journal-title":"Oncogene"},{"key":"1817_CR34","doi-asserted-by":"publisher","first-page":"e1009782","DOI":"10.1371\/journal.pgen.1009782","volume":"18","author":"L Manceau","year":"2022","unstructured":"Manceau L, Albert JR, Lollini P-L, Greenberg MVC, Gilardi-Hebenstreit P, Ribes V. Divergent transcriptional and transforming properties of PAX3-FOXO1 and PAX7-FOXO1 paralogs. PLOS Genet. 2022;18:e1009782.","journal-title":"PLOS Genet"},{"key":"1817_CR35","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1016\/j.cell.2025.03.008","volume":"188","author":"B Kalita","year":"2025","unstructured":"Kalita B, Martinez-Cebrian G, McEvoy J, Allensworth M, Knight M, Magli A, et al. PAX translocations remodel mitochondrial metabolism through altered leucine usage in rhabdomyosarcoma. Cell. 2025;188:2757\u201377.e22.","journal-title":"Cell"},{"key":"1817_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43780-4","volume":"14","author":"Y Asante","year":"2023","unstructured":"Asante Y, Benischke K, Osman I, Ngo QA, Wurth J, Laubscher D, et al. PAX3-FOXO1 uses its activation domain to recruit CBP\/P300 and shape RNA Pol2 cluster distribution. Nat Commun. 2023;14:8361.","journal-title":"Nat Commun"},{"key":"1817_CR37","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3390\/genes14061139","volume":"14","author":"YS Zou","year":"2023","unstructured":"Zou YS, Morsberger L, Hardy M, Ghabrial J, Stinnett V, Murry JB, et al. Complex\/cryptic EWSR1::FLI1\/ERG gene fusions and 1q jumping translocation in pediatric Ewing sarcomas. Genes. 2023;14:1139.","journal-title":"Genes"},{"key":"1817_CR38","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-pathol-011110-130237","volume":"7","author":"SL Lessnick","year":"2012","unstructured":"Lessnick SL, Ladanyi M. Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets. Annu Rev Pathol. 2012;7:145\u201359.","journal-title":"Annu Rev Pathol"},{"key":"1817_CR39","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1093\/nar\/gkq217","volume":"38","author":"V Boeva","year":"2010","unstructured":"Boeva V, Surdez D, Guillon N, Tirode F, Fejes AP, Delattre O, et al. De novo motif identification improves the accuracy of predicting transcription factor binding sites in ChIP-seq data analysis. Nucleic Acids Res. 2010;38:e126.","journal-title":"Nucleic Acids Res"},{"key":"1817_CR40","doi-asserted-by":"crossref","unstructured":"Ruzanov P, Evdokimova V, Pachva MC, Minkovich A, Zhang Z, Langman S, et al. Oncogenic ETS fusions promote DNA damage and proinflammatory responses via pericentromeric RNAs in extracellular vesicles. J Clin Invest. 134:e169470.","DOI":"10.1172\/JCI169470"},{"key":"1817_CR41","doi-asserted-by":"publisher","first-page":"1248753","DOI":"10.3389\/fcell.2023.1248753","volume":"11","author":"M Dupuy","year":"2023","unstructured":"Dupuy M, Lamoureux F, Mullard M, Postec A, Regnier L, Baud\u2019huin M, et al. Ewing sarcoma from molecular biology to the clinic. Front Cell Dev Biol. 2023;11:1248753.","journal-title":"Front Cell Dev Biol"},{"key":"1817_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61725-x","volume":"16","author":"B Galvan","year":"2025","unstructured":"Galvan B, Ongena L, Bruyr J, Fettweis G, Lucarelli E, Lavergne A, et al. Subversion of mRNA degradation pathways by EWSR1::FLI1 represents a therapeutic vulnerability in Ewing sarcoma. Nat Commun. 2025;16:6537.","journal-title":"Nat Commun"},{"key":"1817_CR43","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/sj.leu.2400594","volume":"11","author":"K Yamamoto","year":"1997","unstructured":"Yamamoto K, Hamaguchi H, Nagata K, Kobayashi M, Tanimoto F, Taniwaki M. Establishment of a novel human acute myeloblastic leukemia cell line (YNH-1) with t(16;21), t(1;16) and 12q13 translocations. Leukemia. 1997;11:599\u2013608.","journal-title":"Leukemia"},{"key":"1817_CR44","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1038\/onc.2015.261","volume":"35","author":"AM Sotoca","year":"2016","unstructured":"Sotoca AM, Prange KHM, Reijnders B, Mandoli A, Nguyen LN, Stunnenberg HG, et al. The oncofusion protein FUS\u2013ERG targets key hematopoietic regulators and modulates the all-trans retinoic acid signaling pathway in t(16;21) acute myeloid leukemia. Oncogene. 2016;35:1965\u201376.","journal-title":"Oncogene"},{"key":"1817_CR45","first-page":"4568","volume":"63","author":"DC Shing","year":"2003","unstructured":"Shing DC, McMullan DJ, Roberts P, Smith K, Chin SF, Nicholson J, et al. FUS\/ERG gene fusions in ewing\u2019s tumors. Cancer Res. 2003;63:4568\u201376.","journal-title":"Cancer Res"},{"key":"1817_CR46","first-page":"304","volume":"63","author":"CA French","year":"2003","unstructured":"French CA, Miyoshi I, Kubonishi I, Grier HE, Perez-Atayde AR, Fletcher JA. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res. 2003;63:304\u20137.","journal-title":"Cancer Res"},{"key":"1817_CR47","doi-asserted-by":"publisher","first-page":"e740","DOI":"10.1634\/theoncologist.2018-0477","volume":"24","author":"M Jung","year":"2019","unstructured":"Jung M, Kim S, Lee J, Yoon SO, Park HS, Hong SW, et al. Clinicopathological and preclinical findings of NUT carcinoma: A multicenter study. The Oncologist. 2019;24:e740\u20138.","journal-title":"The Oncologist"},{"key":"1817_CR48","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.cancergencyto.2010.06.007","volume":"203","author":"CA French","year":"2010","unstructured":"French CA. NUT midline carcinoma. Cancer Genet Cytogenet. 2010;203:16\u201320.","journal-title":"Cancer Genet Cytogenet"},{"key":"1817_CR49","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1158\/0008-5472.CAN-23-2545","volume":"83","author":"RT Durall","year":"2023","unstructured":"Durall RT, Huang J, Wojenski L, Huang Y, Gokhale PC, Leeper BA, et al. The BRD4\u2013NUT fusion alone drives malignant transformation of NUT carcinoma. Cancer Res. 2023;83:3846\u201360.","journal-title":"Cancer Res"},{"key":"1817_CR50","doi-asserted-by":"publisher","first-page":"860830","DOI":"10.3389\/fonc.2022.860830","volume":"12","author":"V Moreno","year":"2022","unstructured":"Moreno V, Saluja K, Pina-Oviedo S. NUT carcinoma: Clinicopathologic features, molecular genetics and epigenetics. Front Oncol. 2022;12:860830.","journal-title":"Front Oncol"},{"key":"1817_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36063-5","volume":"14","author":"D Yu","year":"2023","unstructured":"Yu D, Liang Y, Kim C, Jaganathan A, Ji D, Han X, et al. Structural mechanism of BRD4-NUT and p300 bipartite interaction in propagating aberrant gene transcription in chromatin in NUT carcinoma. Nat Commun. 2023;14:378.","journal-title":"Nat Commun"},{"key":"1817_CR52","doi-asserted-by":"publisher","first-page":"101068","DOI":"10.1016\/j.xinn.2025.101068","volume":"7","author":"Y Zhang","year":"2026","unstructured":"Zhang Y, Zhang Q, Hao Y, Luo J, Piao Y, Wang W, et al. International guidelines on the diagnosis and treatment of NUT carcinoma. The Innovation. 2026;7:101068.","journal-title":"The Innovation"},{"key":"1817_CR53","doi-asserted-by":"publisher","first-page":"189215","DOI":"10.1016\/j.bbcan.2024.189215","volume":"1879","author":"C Ren","year":"2024","unstructured":"Ren C, Liu J, Hornicek FJ, Yue B, Duan Z. Advances of SS18-SSX fusion gene in synovial sarcoma: emerging novel functions and therapeutic. Biochim Biophys Acta BBA - Rev Cancer. 2024;1879:189215.","journal-title":"Biochim Biophys Acta BBA - Rev Cancer"},{"key":"1817_CR54","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1038\/s41594-023-01096-3","volume":"30","author":"NS Benabdallah","year":"2023","unstructured":"Benabdallah NS, Dalal V, Scott RW, Marcous F, Sotiriou A, Kommoss FKF, et al. Aberrant gene activation in synovial sarcoma relies on SSX specificity and increased PRC1.1 stability. Nat Struct Mol Biol. 2023;30:1640\u201352.","journal-title":"Nat Struct Mol Biol"},{"key":"1817_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-024-00539-w","volume":"13","author":"P Li","year":"2024","unstructured":"Li P, Zhai Z, Fan Y, Li W, Ke M, Li X, et al. Condensate remodeling reorganizes innate SS18 in synovial sarcomagenesis. Oncogenesis. 2024;13:38.","journal-title":"Oncogenesis"},{"key":"1817_CR56","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.3390\/curroncol28030177","volume":"28","author":"AM Gazendam","year":"2021","unstructured":"Gazendam AM, Popovic S, Munir S, Parasu N, Wilson D, Ghert M. Synovial Sarcoma: a Clinical Review. Curr Oncol. 2021;28:1909\u201320.","journal-title":"Curr Oncol"},{"key":"1817_CR57","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1158\/1078-0432.CCR-08-0168","volume":"14","author":"JP Koivunen","year":"2008","unstructured":"Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008;14:4275\u201383.","journal-title":"Clin Cancer Res"},{"key":"1817_CR58","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1684\/bdc.2012.1604","volume":"99","author":"V Fallet","year":"2012","unstructured":"Fallet V, Toper C, Antoine M, Cadranel J, Wislez M. Crizotinib, modalit\u00e9s pratiques d\u2019un traitement personnalis\u00e9. Bull Cancer. 2012;99:787\u201391.","journal-title":"Bull Cancer"},{"key":"1817_CR59","doi-asserted-by":"crossref","unstructured":"Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2015;373:1582.","DOI":"10.1056\/NEJMx150034"},{"key":"1817_CR60","first-page":"CD013453","volume":"2022","author":"LB Cameron","year":"2022","unstructured":"Cameron LB, Hitchen N, Chandran E, Morris T, Manser R, Solomon BJ, et al. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. Cochrane Database Syst Rev. 2022;2022:CD013453.","journal-title":"Cochrane Database Syst Rev"},{"key":"1817_CR61","doi-asserted-by":"publisher","first-page":"75372","DOI":"10.18632\/oncotarget.18536","volume":"8","author":"Q Zhu","year":"2017","unstructured":"Zhu Q, Hu H, Jiang F, Guo CY, Yang XW, Liu X, et al. Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC. Oncotarget. 2017;8:75372\u201380.","journal-title":"Oncotarget"},{"key":"1817_CR62","doi-asserted-by":"crossref","unstructured":"Casaluce F, Sgambato A, Sacco PC, Palazzolo G, Maione P, Rossi A, et al. Resistance to crizotinib in advanced non-small cell lung cancer (NSCLC) with ALK rearrangement: mechanisms, treatment strategies and new targeted therapies. Curr Clin Pharmacol n.d.;11:77\u201387.","DOI":"10.2174\/1574884711666160502124134"},{"key":"1817_CR63","first-page":"S502","volume":"6","author":"S Revannasiddaiah","year":"2014","unstructured":"Revannasiddaiah S, Thakur P, Bhardwaj B, Susheela SP, Madabhavi I. Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC\/ATS\/ERS classification. J Thorac Dis. 2014;6:S502\u201325.","journal-title":"J Thorac Dis"},{"key":"1817_CR64","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1158\/1078-0432.CCR-14-0107","volume":"20","author":"T Nakaoku","year":"2014","unstructured":"Nakaoku T, Tsuta K, Ichikawa H, Shiraishi K, Sakamoto H, Enari M, et al. Druggable oncogene fusions in invasive mucinous lung adenocarcinoma. Clin Cancer Res. 2014;20:3087\u201393.","journal-title":"Clin Cancer Res"},{"key":"1817_CR65","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1158\/2159-8290.CD-18-0036","volume":"8","author":"C Heining","year":"2018","unstructured":"Heining C, Horak P, Uhrig S, Codo PL, Klink B, Hutter B, et al. NRG1 fusions in KRAS wild-type pancreatic cancer. Cancer Discov. 2018;8:1087\u201395.","journal-title":"Cancer Discov"},{"key":"1817_CR66","doi-asserted-by":"publisher","first-page":"9226","DOI":"10.1073\/pnas.1332660100","volume":"100","author":"CB Chen","year":"2003","unstructured":"Chen CB, Chernis GA, Hoang VQ, Landgraf R. Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. Proc Natl Acad Sci USA. 2003;100:9226\u201331.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1817_CR67","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1073\/pnas.96.9.4995","volume":"96","author":"LN Klapper","year":"1999","unstructured":"Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M, et al. The ErbB-2\/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA. 1999;96:4995\u20135000.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1817_CR68","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.ccell.2021.07.015","volume":"39","author":"CAW Geuijen","year":"2021","unstructured":"Geuijen CAW, De Nardis C, Maussang D, Rovers E, Gallenne T, Hendriks LJA, et al. Unbiased combinatorial screening identifies a bispecific IgG1 that potently inhibits HER3 signaling via HER2-guided ligand blockade. Cancer Cell. 2021;39:1163\u20134.","journal-title":"Cancer Cell"},{"key":"1817_CR69","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1158\/2159-8290.CD-21-1119","volume":"12","author":"AM Schram","year":"2022","unstructured":"Schram AM, Odintsov I, Espinosa-Cotton M, Khodos I, Sisso WJ, Mattar MS, et al. Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements. Cancer Discov. 2022;12:1233\u201347.","journal-title":"Cancer Discov"},{"key":"1817_CR70","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41580-024-00729-9","volume":"25","author":"JM Tsai","year":"2024","unstructured":"Tsai JM, Nowak RP, Ebert BL, Fischer ES. Targeted protein degradation: from mechanisms to clinic. Nat Rev Mol Cell Biol. 2024;25:740\u201357.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1817_CR71","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1039\/D4CS00243A","volume":"54","author":"SP van Wier","year":"2025","unstructured":"van Wier SP, Beekman AM. Peptide design to control protein\u2013protein interactions. Chem Soc Rev. 2025;54:1684\u201398.","journal-title":"Chem Soc Rev"},{"key":"1817_CR72","doi-asserted-by":"publisher","first-page":"94780","DOI":"10.18632\/oncotarget.21933","volume":"8","author":"W Sun","year":"2017","unstructured":"Sun W, Rojas Y, Wang H, Yu Y, Wang Y, Chen Z, et al. EWS-FLI1 and RNA helicase a interaction inhibitor YK-4-279 inhibits growth of neuroblastoma. Oncotarget. 2017;8:94780\u201392.","journal-title":"Oncotarget"},{"key":"1817_CR73","doi-asserted-by":"publisher","first-page":"1416946","DOI":"10.3389\/fcell.2024.1416946","volume":"12","author":"BZ Stanton","year":"2024","unstructured":"Stanton BZ, Pomella S. Epigenetic determinants of fusion-driven sarcomas: paradigms and challenges. Front Cell Dev Biol. 2024;12:1416946.","journal-title":"Front Cell Dev Biol"},{"key":"1817_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45902-y","volume":"15","author":"YY Kim","year":"2024","unstructured":"Kim YY, Gryder BE, Sinniah R, Peach ML, Shern JF, Abdelmaksoud A, et al. KDM3B inhibitors disrupt the oncogenic activity of PAX3-FOXO1 in fusion-positive rhabdomyosarcoma. Nat Commun. 2024;15:1703.","journal-title":"Nat Commun"},{"key":"1817_CR75","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41388-022-02533-1","volume":"42","author":"J Mo","year":"2023","unstructured":"Mo J, Tan K, Dong Y, Lu W, Liu F, Mei Y, et al. Therapeutic targeting the oncogenic driver EWSR1::FLI1 in Ewing sarcoma through inhibition of the FACT complex. Oncogene. 2023;42:11\u201325.","journal-title":"Oncogene"},{"key":"1817_CR76","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/hmg\/dds486","volume":"22","author":"SV Williams","year":"2013","unstructured":"Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet. 2013;22:795\u2013803.","journal-title":"Hum Mol Genet"},{"key":"1817_CR77","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","volume":"38","author":"M Katoh","year":"2016","unstructured":"Katoh M. FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (review). Int J Mol Med. 2016;38:3\u201315.","journal-title":"Int J Mol Med"},{"key":"1817_CR78","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.2147\/OTT.S492659","volume":"17","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zhu J, Liu S, Sun Z, Wen G, Huang D, et al. CRISPR-Cas13a targeting the FGFR3-TACC3 fusion gene inhibits proliferation of bladder cancer cells in vitro and in vivo. OncoTargets Ther. 2024;17:1197\u2013207.","journal-title":"OncoTargets Ther"},{"key":"1817_CR79","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S0165-4608(96)00326-3","volume":"97","author":"C Desmaze","year":"1997","unstructured":"Desmaze C, Brizard F, Turc-Carel C, Melot T, Delattre O, Thomas G, et al. Multiple chromosomal mechanisms generate an EWS\/FLI1 or an EWS\/ERG fusion gene in ewing tumors. Cancer Genet Cytogenet. 1997;97:12\u20139.","journal-title":"Cancer Genet Cytogenet"},{"key":"1817_CR80","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1158\/0008-5472.CAN-05-3293","volume":"66","author":"JA Toretsky","year":"2006","unstructured":"Toretsky JA, Erkizan V, Levenson A, Abaan OD, Parvin JD, Cripe TP, et al. Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase a. Cancer Res. 2006;66:5574\u201381.","journal-title":"Cancer Res"},{"key":"1817_CR81","doi-asserted-by":"publisher","first-page":"172","DOI":"10.18632\/oncotarget.454","volume":"3","author":"JS Barber-Rotenberg","year":"2012","unstructured":"Barber-Rotenberg JS, Selvanathan SP, Kong Y, Erkizan HV, Snyder TM, Hong SP, et al. Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1. Oncotarget. 2012;3:172\u201382.","journal-title":"Oncotarget"},{"key":"1817_CR82","doi-asserted-by":"publisher","first-page":"11500","DOI":"10.1200\/JCO.2021.39.15_suppl.11500","volume":"39","author":"JA Ludwig","year":"2021","unstructured":"Ludwig JA, Federman NC, Anderson PM, Macy ME, Riedel RF, Davis LE, et al. TK216 for relapsed\/refractory Ewing sarcoma: Interim phase 1\/2 results. J Clin Oncol. 2021;39:11500.","journal-title":"J Clin Oncol"},{"key":"1817_CR83","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00280-017-3382-x","volume":"80","author":"PJ Grohar","year":"2017","unstructured":"Grohar PJ, Glod J, Peer CJ, Sissung TM, Arnaldez FI, Long L, et al. A phase I\/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS\u2013FLI1 fusion transcript. Cancer Chemother Pharmacol. 2017;80:645\u201352.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1817_CR84","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1158\/1078-0432.CCR-15-2624","volume":"22","author":"CL Osgood","year":"2016","unstructured":"Osgood CL, Maloney N, Kidd CG, Kitchen-Goosen S, Segars L, Gebregiorgis M, et al. Identification of mithramycin analogs with improved targeting of the EWS-FLI1 transcription factor. Clin Cancer Res. 2016;22:4105\u201318.","journal-title":"Clin Cancer Res"},{"key":"1817_CR85","doi-asserted-by":"publisher","first-page":"5089","DOI":"10.1038\/onc.2012.525","volume":"32","author":"S Sankar","year":"2013","unstructured":"Sankar S, Bell R, Stephens B, Zhuo R, Sharma S, Bearss DJ, et al. Mechanism and relevance of EWS\/FLI-mediated transcriptional repression in Ewing sarcoma. Oncogene. 2013;32:5089\u2013100.","journal-title":"Oncogene"},{"key":"1817_CR86","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1593\/neo.101202","volume":"13","author":"PJ Grohar","year":"2011","unstructured":"Grohar PJ, Griffin LB, Yeung C, Chen Q-R, Pommier Y, Khanna C, et al. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia. 2011;13:145\u201353.","journal-title":"Neoplasia"},{"key":"1817_CR87","doi-asserted-by":"publisher","first-page":"6657","DOI":"10.1158\/0008-5472.CAN-16-0568","volume":"76","author":"ML Harlow","year":"2016","unstructured":"Harlow ML, Maloney N, Roland J, Guillen Navarro MJ, Easton MK, Kitchen-Goosen SM, et al. Lurbinectedin inactivates the Ewing sarcoma oncoprotein EWS-FLI1 by redistributing it within the nucleus. Cancer Res. 2016;76:6657\u201368.","journal-title":"Cancer Res"},{"key":"1817_CR88","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/mt.2016.93","volume":"24","author":"DD Rao","year":"2016","unstructured":"Rao DD, Jay C, Wang Z, Luo X, Kumar P, Eysenbach H, et al. Preclinical justification of pbi-shRNA EWS\/FLI1 lipoplex (LPX) treatment for Ewing\u2019s sarcoma. Mol Ther. 2016;24:1412\u201322.","journal-title":"Mol Ther"},{"key":"1817_CR89","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1158\/2159-8290.CD-14-0014","volume":"4","author":"CA French","year":"2014","unstructured":"French CA, Rahman S, Walsh EM, K\u00fchnle S, Grayson AR, Lemieux ME, et al. NSD3-NUT fusion oncoprotein in NUT midline carcinoma: Implications for a novel oncogenic mechanism. Cancer Discov. 2014;4:928\u201341.","journal-title":"Cancer Discov"},{"key":"1817_CR90","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1038\/sj.onc.1210852","volume":"27","author":"CA French","year":"2008","unstructured":"French CA, Ramirez CL, Kolmakova J, Hickman TT, Cameron MJ, Thyne ME, et al. BRD\u2013NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene. 2008;27:2237\u201342.","journal-title":"Oncogene"},{"key":"1817_CR91","doi-asserted-by":"publisher","first-page":"102826","DOI":"10.1016\/j.critrevonc.2019.102826","volume":"144","author":"M Salati","year":"2019","unstructured":"Salati M, Baldessari C, Bonetti LR, Messina C, Merz V, Cerbelli B, et al. NUT midline carcinoma: Current concepts and future perspectives of a novel tumour entity. Crit Rev Oncol Hematol. 2019;144:102826.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1817_CR92","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature. 2010;468:1067\u201373.","journal-title":"Nature"},{"key":"1817_CR93","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1002\/cncr.27555","volume":"118","author":"G Mastrangelo","year":"2012","unstructured":"Mastrangelo G, Coindre J-M, Ducimeti\u00e8re F, Dei Tos AP, Fadda E, Blay J-Y, et al. Incidence of soft tissue sarcoma and beyond: A population-based prospective study in 3 European regions. Cancer. 2012;118:5339\u201348.","journal-title":"Cancer"},{"key":"1817_CR94","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/pbc.26206","volume":"64","author":"S Stegmaier","year":"2017","unstructured":"Stegmaier S, Leuschner I, Poremba C, Ladenstein R, Kazanowska B, Ljungman G, et al. The prognostic impact of SYT-SSX fusion type and histological grade in pediatric patients with synovial sarcoma treated according to the CWS (cooperative weichteilsarkom studie) trials. Pediatr Blood Cancer. 2017;64:89\u201395.","journal-title":"Pediatr Blood Cancer"},{"key":"1817_CR95","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","volume":"15","author":"E Cocco","year":"2018","unstructured":"Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15:731\u201347.","journal-title":"Nat Rev Clin Oncol"},{"key":"1817_CR96","doi-asserted-by":"publisher","first-page":"viii23","DOI":"10.1093\/annonc\/mdz282","volume":"30","author":"A Drilon","year":"2019","unstructured":"Drilon A. TRK inhibitors in TRK fusion-positive cancers. Ann Oncol. 2019;30:viii23\u201330.","journal-title":"Ann Oncol"},{"key":"1817_CR97","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1200\/JCO.24.00020","volume":"42","author":"PA Meyers","year":"2024","unstructured":"Meyers PA, Federman N, Daw N, Anderson PM, Davis LE, Kim A, et al. Open-label, multi-center, phase 1\/2, first-in-human trial of TK216: A first-generation EWS::FLI1 fusion protein antagonist in Ewing sarcoma. J Clin Oncol. 2024;42:3725\u201334.","journal-title":"J Clin Oncol"},{"key":"1817_CR98","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41571-020-0408-9","volume":"18","author":"A Drilon","year":"2021","unstructured":"Drilon A, Jenkins C, Iyer S, Schoenfeld A, Keddy C, Davare MA. ROS1-dependent cancers \u2014 biology, diagnostics and therapeutics. Nat Rev Clin Oncol. 2021;18:35\u201355.","journal-title":"Nat Rev Clin Oncol"},{"key":"1817_CR99","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-07-3293","volume":"68","author":"IB Weinstein","year":"2008","unstructured":"Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 2008;68:3077\u201380.","journal-title":"Cancer Res"},{"key":"1817_CR100","doi-asserted-by":"publisher","first-page":"1042525","DOI":"10.3389\/fonc.2022.1042525","volume":"12","author":"M Nannini","year":"2022","unstructured":"Nannini M, Repaci A, Ricco G, Ianni M, Golemi A, Maiolo V, et al. Case report: dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma. Front Oncol. 2022;12:1042525.","journal-title":"Front Oncol"},{"key":"1817_CR101","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.lungcan.2021.04.017","volume":"156","author":"G Pall","year":"2021","unstructured":"Pall G, Gautschi O. Advances in the treatment of RET-fusion-positive lung cancer. Lung Cancer. 2021;156:136\u20139.","journal-title":"Lung Cancer"},{"key":"1817_CR102","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/oncolo\/oyac264","volume":"28","author":"S Novello","year":"2023","unstructured":"Novello S, Califano R, Reinmuth N, Tamma A, Puri T. RET fusion-positive non-small cell lung cancer: The evolving treatment landscape. Oncologist. 2023;28:402\u201313.","journal-title":"Oncologist"},{"key":"1817_CR103","doi-asserted-by":"publisher","first-page":"10123","DOI":"10.2147\/OTT.S262653","volume":"13","author":"C-W Wu","year":"2020","unstructured":"Wu C-W, Yang C-Y, Chang Y-L, Shih J-Y. Successful management of a ROS1-rearranged pulmonary pleomorphic carcinoma using serial tyrosine kinase inhibitors. OncoTargets Ther. 2020;13:10123\u20137.","journal-title":"OncoTargets Ther"},{"key":"1817_CR104","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","volume":"6","author":"JF Gainor","year":"2016","unstructured":"Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016;6:1118\u201333.","journal-title":"Cancer Discov"},{"key":"1817_CR105","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.annonc.2020.10.599","volume":"32","author":"V Subbiah","year":"2021","unstructured":"Subbiah V, Shen T, Terzyan SS, Liu X, Hu X, Patel KP, et al. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann Oncol. 2021;32:261\u20138.","journal-title":"Ann Oncol"},{"key":"1817_CR106","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41571-020-0377-z","volume":"17","author":"R Guo","year":"2020","unstructured":"Guo R, Luo J, Chang J, Rekhtman N, Arcila M, Drilon A. MET-dependent solid tumors: Molecular diagnosis and targeted therapy. Nat Rev Clin Oncol. 2020;17:569\u201387.","journal-title":"Nat Rev Clin Oncol"},{"key":"1817_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-017-0032-z","volume":"1","author":"SH Shin","year":"2017","unstructured":"Shin SH, Bode AM, Dong Z. Addressing the challenges of applying precision oncology. NPJ Precis Oncol. 2017;1:28.","journal-title":"NPJ Precis Oncol"},{"key":"1817_CR108","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.lungcan.2017.04.004","volume":"108","author":"FH Knebel","year":"2017","unstructured":"Knebel FH, Bettoni F, Shimada AK, Cruz M, Alessi JV, Negr\u00e3o MV, et al. Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC. Lung Cancer. 2017;108:238\u201341.","journal-title":"Lung Cancer"},{"key":"1817_CR109","doi-asserted-by":"publisher","first-page":"864666","DOI":"10.3389\/fonc.2022.864666","volume":"12","author":"F Liu","year":"2022","unstructured":"Liu F, Wei Y, Zhang H, Jiang J, Zhang P, Chu Q. NTRK fusion in non-small cell lung cancer: diagnosis, therapy, and TRK inhibitor resistance. Front Oncol. 2022;12:864666.","journal-title":"Front Oncol"},{"key":"1817_CR110","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-19-0631","volume":"19","author":"MA Krook","year":"2020","unstructured":"Krook MA, Lenyo A, Wilberding M, Barker H, Dantuono M, Bailey KM, et al. Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma. Mol Cancer Ther. 2020;19:847\u201357.","journal-title":"Mol Cancer Ther"},{"key":"1817_CR111","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","volume":"7","author":"L Goyal","year":"2017","unstructured":"Goyal L, Saha SK, Liu LY, Siravegna G, Leshchiner I, Ahronian LG, et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 2017;7:252\u201363.","journal-title":"Cancer Discov"},{"key":"1817_CR112","first-page":"9619","volume":"47","author":"SP Selvanathan","year":"2019","unstructured":"Selvanathan SP, Graham GT, Grego AR, Baker TM, Hogg JR, Simpson M, et al. EWS\u2013FLI1 modulated alternative splicing of ARID1A reveals novel oncogenic function through the BAF complex. Nucleic Acids Res. 2019;47:9619\u201336.","journal-title":"Nucleic Acids Res"},{"key":"1817_CR113","doi-asserted-by":"publisher","first-page":"55924","DOI":"10.18632\/oncotarget.10482","volume":"7","author":"R Costa","year":"2016","unstructured":"Costa R, Carneiro BA, Taxter T, Tavora FA, Kalyan A, Pai SA, et al. FGFR3-TACC3 fusion in solid tumors: Mini review. Oncotarget. 2016;7:55924\u201338.","journal-title":"Oncotarget"},{"key":"1817_CR114","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/j.ejca.2010.04.002","volume":"46","author":"T Sasaki","year":"2010","unstructured":"Sasaki T, Rodig SJ, Chirieac LR, J\u00e4nne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer. 2010;46:1773\u201380.","journal-title":"Eur J Cancer"},{"key":"1817_CR115","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.semcancer.2017.11.006","volume":"50","author":"M Wachtel","year":"2018","unstructured":"Wachtel M, Sch\u00e4fer BW. PAX3-FOXO1: Zooming in on an \u201cundruggable\u201d target. Semin Cancer Biol. 2018;50:115\u201323.","journal-title":"Semin Cancer Biol"},{"key":"1817_CR116","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1158\/2159-8290.CD-16-1297","volume":"7","author":"BE Gryder","year":"2017","unstructured":"Gryder BE, Yohe ME, Chou HC, Zhang X, Marques J, Wachtel M, et al. PAX3-FOXO1 establishes myogenic super enhancers and confers BET bromodomain vulnerability. Cancer Discov. 2017;7:884\u201399.","journal-title":"Cancer Discov"},{"key":"1817_CR117","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1158\/0008-5472.CAN-14-1246","volume":"75","author":"V Thalhammer","year":"2015","unstructured":"Thalhammer V, Lopez-Garcia LA, Herrero-Martin D, Hecker R, Laubscher D, Gierisch ME, et al. PLK1 phosphorylates PAX3-FOXO1, the inhibition of which triggers regression of alveolar rhabdomyosarcoma. Cancer Res. 2015;75:98\u2013110.","journal-title":"Cancer Res"},{"key":"1817_CR118","doi-asserted-by":"publisher","first-page":"e193221","DOI":"10.1172\/jci.insight.193221","volume":"11","author":"W Ying","year":"2026","unstructured":"Ying W, Yu J, Wang X, Liu J, Deng B, Shao X, et al. Therapeutic targeting of YOD1 disrupts the PAX-FOXO1\/N-myc feedback loop in rhabdomyosarcoma. JCI Insight. 2026;11:e193221.","journal-title":"JCI Insight"},{"key":"1817_CR119","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01454-0","volume":"22","author":"D Sun","year":"2024","unstructured":"Sun D, Xing X, Wang Y, Hou H. MET fusions are targetable genomic variants in the treatment of advanced malignancies. Cell Commun Signal. 2024;22:20.","journal-title":"Cell Commun Signal"},{"key":"1817_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cllc.2020.10.013","volume":"22","author":"N Haratake","year":"2021","unstructured":"Haratake N, Seto T. NTRK fusion-positive non\u2013small-cell lung cancer: the diagnosis and targeted therapy. Clin Lung Cancer. 2021;22:1\u20135.","journal-title":"Clin Lung Cancer"},{"key":"1817_CR121","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.cancergen.2021.10.005","volume":"258-259","author":"E Aref-Eshghi","year":"2021","unstructured":"Aref-Eshghi E, Lin F, Li MM, Zhong Y. The oncogenic roles of NTRK fusions and methods of molecular diagnosis. Cancer Genet. 2021;258-259:110\u20139.","journal-title":"Cancer Genet"},{"key":"1817_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104234","volume":"194","author":"G Hagopian","year":"2024","unstructured":"Hagopian G, Nagasaka M. Oncogenic fusions: targeting NTRK. Crit Rev Oncol Hematol. 2024;194:104234.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1817_CR123","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/DAD.0000000000001780","volume":"43","author":"D Kim","year":"2021","unstructured":"Kim D, Compres EV, Zhang B, Khan AU, Sunshine JC, Quan VL, et al. A series of RET fusion spitz neoplasms with plaque-like silhouette and dyscohesive nesting of epithelioid melanocytes. Am J Dermatopathol. 2021;43:243.","journal-title":"Am J Dermatopathol"},{"key":"1817_CR124","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","volume":"371","author":"AT Shaw","year":"2014","unstructured":"Shaw AT, Ou S-HI, Bang Y-J, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1-rearranged non\u2013small-cell lung cancer. N Engl J Med. 2014;371:1963\u201371.","journal-title":"N Engl J Med"},{"key":"1817_CR125","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1038\/s41388-017-0081-3","volume":"37","author":"JA Hanna","year":"2018","unstructured":"Hanna JA, Garcia MR, Lardennois A, Leavey PJ, Maglic D, Fagnan A, et al. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma. Oncogene. 2018;37:1991\u20132007.","journal-title":"Oncogene"},{"key":"1817_CR126","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1200\/JCO.1998.16.4.1248","volume":"16","author":"E de Alava","year":"1998","unstructured":"de Alava E, Kawai A, Healey JH, Fligman I, Meyers PA, Huvos AG, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing\u2019s sarcoma. J Clin Oncol. 1998;16:1248\u201355.","journal-title":"J Clin Oncol"},{"key":"1817_CR127","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/gcc.22336","volume":"55","author":"S Chen","year":"2016","unstructured":"Chen S, Deniz K, Sung Y-S, Zhang L, Dry S, Antonescu CR. Ewing sarcoma with ERG gene rearrangements: a molecular study focusing on the prevalence of FUS-ERG and common pitfalls in detecting EWSR1-ERG fusions by FISH. Genes Chromosomes Cancer. 2016;55:340\u20139.","journal-title":"Genes Chromosomes Cancer"},{"key":"1817_CR128","doi-asserted-by":"publisher","first-page":"37509","DOI":"10.18632\/oncotarget.26493","volume":"9","author":"M Ishii","year":"2018","unstructured":"Ishii M, Suehara Y, Sano K, Kohsaka S, Hayashi T, Kazuno S, et al. Proteomic signatures corresponding to the SS18\/SSX fusion gene in synovial sarcoma. Oncotarget. 2018;9:37509\u201319.","journal-title":"Oncotarget"},{"key":"1817_CR129","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s40265-020-01330-y","volume":"80","author":"SM Hoy","year":"2020","unstructured":"Hoy SM. Pemigatinib: First approval. Drugs. 2020;80:923\u20139.","journal-title":"Drugs"},{"key":"1817_CR130","doi-asserted-by":"crossref","unstructured":"Heigener DF, Reck M. Crizotinib. Recent results cancer res fortschritte krebsforsch progres. Dans Rech Sur Cancer. 2018;211:57\u201365.","DOI":"10.1007\/978-3-319-91442-8_4"},{"key":"1817_CR131","doi-asserted-by":"publisher","first-page":"104019","DOI":"10.1016\/j.critrevonc.2023.104019","volume":"187","author":"S-HI Ou","year":"2023","unstructured":"Ou S-HI, Lee ATM, Nagasaka M. From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC. Crit Rev Oncol Hematol. 2023;187:104019.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1817_CR132","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1159\/000533822","volume":"16","author":"H Kato","year":"2023","unstructured":"Kato H, Kano S, Yasui Y, Nojiri Y, Yoshimitsu M, Nakamura M, et al. Effectiveness treatment of a BRAF-ZKSCAN5 fusion gene melanoma case with dabrafenib\/trametinib. Case Rep Oncol. 2023;16:1007\u201312.","journal-title":"Case Rep Oncol"},{"key":"1817_CR133","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.3390\/cancers11091262","volume":"11","author":"KC Schreck","year":"2019","unstructured":"Schreck KC, Grossman SA, Pratilas CA. BRAF mutations and the utility of RAF and MEK inhibitors in primary brain tumors. Cancers. 2019;11:1262.","journal-title":"Cancers"},{"key":"1817_CR134","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1158\/1078-0432.CCR-21-2664","volume":"28","author":"AB Lassman","year":"2022","unstructured":"Lassman AB, Sep\u00falveda-S\u00e1nchez JM, Cloughesy TF, Gil-Gil MJ, Puduvalli VK, Raizer JJ, et al. Infigratinib in patients with recurrent gliomas and FGFR alterations: a multicenter phase II study. Clin Cancer Res. 2022;28:2270\u20137.","journal-title":"Clin Cancer Res"},{"key":"1817_CR135","doi-asserted-by":"publisher","first-page":"5555","DOI":"10.3390\/cancers15235555","volume":"15","author":"A Picca","year":"2023","unstructured":"Picca A, Sansone G, Santonocito OS, Mazzanti CM, Sanson M, Di Stefano AL. Diffuse gliomas with FGFR3-TACC3 fusions: oncogenic mechanisms, hallmarks, and therapeutic perspectives. Cancers. 2023;15:5555.","journal-title":"Cancers"},{"key":"1817_CR136","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1634\/theoncologist.2020-0379","volume":"26","author":"J Cadranel","year":"2021","unstructured":"Cadranel J, Liu SV, Duruisseaux M, Branden E, Goto Y, Weinberg BA, et al. Therapeutic potential of afatinib in NRG1 fusion-driven solid tumors: a case series. The Oncologist. 2021;26:7\u201316.","journal-title":"The Oncologist"},{"key":"1817_CR137","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.phrs.2017.04.022","volume":"121","author":"R Roskoski","year":"2017","unstructured":"Roskoski R. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers ROS1. Pharmacol Res. 2017;121:202\u201312.","journal-title":"Pharmacol Res"},{"key":"1817_CR138","doi-asserted-by":"publisher","first-page":"vdaa132","DOI":"10.1093\/noajnl\/vdaa132","volume":"2","author":"BC Parker Kerrigan","year":"2020","unstructured":"Parker Kerrigan BC, Ledbetter D, Kronowitz M, Phillips L, Gumin J, Hossain A, et al. RNAi technology targeting the FGFR3-TACC3 fusion breakpoint: an opportunity for precision medicine. Neuro-Oncol Adv. 2020;2:vdaa132.","journal-title":"Neuro-Oncol Adv"},{"key":"1817_CR139","doi-asserted-by":"crossref","unstructured":"Taulli R, Accornero P, Follenzi A, Mangano T, Morotti A, Scuoppo C, et al. RNAi technology and lentiviral delivery as a powerful tool to suppress Tpr-Met-mediated tumorigenesis. Cancer Gene Ther. 2005;12:456\u201363.","DOI":"10.1038\/sj.cgt.7700815"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01817-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01817-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01817-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T09:04:57Z","timestamp":1779095097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01817-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":139,"alternative-id":["1817"],"URL":"https:\/\/doi.org\/10.1038\/s41401-026-01817-6","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The corresponding author, Bo Yang, is a member of the Editorial Board of the journal Acta Pharmacologica Sinica, but she has not been involved in the peer-review or decision-making process for this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}